Articles tagged with Parkinsons Disease
A study published in BMC Medicine found that simvastatin is associated with a lower incidence of dementia and Parkinson's disease. The researchers analyzed data from over 700,000 simvastatin users and more than 50,000 atorvastatin users to confirm the benefits of simvastatin on these conditions.
Researchers found that transplanted stem cells triggered the brain's self-repair mechanisms by boosting nerve survival and blood vessel development. The study suggests that stem cells may be more effective at repairing damaged brain tissue than previously thought.
Researchers have identified two separate brain networks affected by Parkinson's disease, one regulating movement and the other cognitive function. The study found that standard treatments alter the motor network but not the cognitive network, highlighting the need for new treatments to target cognition.
Researchers identified risk factors for hallucinations, sleepiness and swelling in people with early Parkinson's disease, including being male, having multiple health problems and taking certain medications. The study found nearly half of participants developed swelling within four years of treatment.
A pooled analysis of data from previous studies suggests that cigarette smoking is associated with a reduced risk for developing Parkinson’s disease. Current and long-term smokers had the lowest risk, while those who quit smoking up to 25 years prior to diagnosis also showed a significant decrease in risk.
A recent study reveals that depression is common in early Parkinson's disease diagnosis, with 27% of subjects screening positive for depression. Untreated depression can significantly impact daily life activities and overall quality of life.
In mice and human patients, researchers found that crippling of protective enzyme Prx2 leads to death of dopamine-producing neurons in Parkinson's disease. Activating Prx2 prevents neuronal loss, suggesting it as a beneficial target for PD treatment.
Researchers at University of Helsinki discover novel neurotrophic factor CDNF that protects and rescues damaged dopamine neurons, recovering function after experimental lesion. This breakthrough may lead to new treatment strategies for Parkinson's disease.
The Parkinson's Institute has received a $1 million grant from the Valley Foundation to support its STOP PD program, which aims to identify compounds to halt Parkinson's disease progression. The new facility will enable expanded research and patient services, offering improved care for those diagnosed with Parkinson's.
The Penn Udall Center will focus on dementia and Parkinson's disease, with objectives including developing a new rating scale for activities of daily living and studying the neural basis of cognitive deficits in Parkinson's disease. The center aims to improve care and treatment for patients and train physicians.
A novel gene therapy technique has been found safe and effective in reducing worsening symptoms of Parkinson's disease in advanced patients. The treatment, which involves injecting genes into one side of the brain to restore a critical neurotransmitter called GABA, showed a 27% improvement in symptoms among participants.
A large-scale study found that high levels of urate in the blood are strongly associated with a reduced risk of Parkinson's disease. Urate, a normal component of blood, may have beneficial effects due to its antioxidant properties.
A new gene therapy clinical trial has reported promising results in improving motor function for patients with Parkinson's disease. The study found significant improvements in both the off-state and on-medication phases, with some patients showing impressive gains of up to 65 percent.
A Phase 1 study using an adeno-associated virus vector to deliver an inhibitory gene to the subthalamic nucleus demonstrated a lack of adverse events and statistically significant improvements in clinical symptoms and brain metabolism. The treated side showed notable improvement, with sustained benefits observed over 12 months.
A study published in The Lancet found that gene therapy can safely alleviate symptoms of Parkinson's disease, with significant improvements seen in movement and motor scores. The treatment involves injecting genetic information directly into brain cells, eliminating the need for indwelling hardware associated with deep-brain stimulation.
Scientists have discovered a potential new treatment for Parkinson's disease by inhibiting the action of an enzyme called SIRT2. Blocking this pathway is believed to protect neurons damaged in Parkinson's from the toxic effects of alpha-synuclein, a protein that accumulates in the brains of patients.
A novel signaling pathway has been identified as being altered by genetic mutations in Parkinson's disease, affecting cellular function and potentially leading to new therapeutic targets. The research found that mitochondrial protein PINK1 plays a crucial role in protecting cells from oxidative stress and promoting cell survival.
The study reveals a novel anti-apoptotic signaling pathway disrupted by PINK1 mutations, suggesting a potential target for therapeutic intervention in Parkinson's disease. Increasing evidence links single-copy mutations in PINK1 to the development of later-onset PD.
A new study from Mayo Clinic researchers reveals that the joint effects of common DNA variations in several genes within a well-defined biological pathway largely explain why some people develop Parkinson’s disease. The findings also predict with great accuracy at what age people might develop their first symptoms.
Researchers have found that Isradipine slows the destruction of dopamine-producing neurons in a mouse model, potentially preventing Parkinson's disease or slowing its progression. The study aims to develop clinical trials in humans to test the drug's efficacy.
Researchers from Yale University and others report that injecting human neural stem cells into primates with severe Parkinson's disease improved symptoms such as tremors and motor function. The study found that the stem cells survived, migrated, and had a functional impact, suggesting a potential therapeutic value.
Researchers at Northwestern University have discovered a drug that slows and may halt the progression of Parkinson's disease by rejuvenating aging dopamine cells. Isradipine, a widely used hypertension medication, restores stressed-out dopamine neurons to their youthful state, potentially extending the time L-DOPA works effectively.
A study found that exposure to pesticides increases the risk of Parkinson's disease, as does traumatic head injury, with higher levels of exposure associated with greater risk. The two factors are potentially modifiable, suggesting opportunities for prevention and reduction.
Researchers at Mayo Clinic have discovered a correlation between violent rapid eye movement sleep behavior disorder and eventual onset of parkinsonism or dementia. Patients with the disorder may be exhibiting early signs of an evolving neurodegenerative disease caused by abnormal synuclein protein clumps.
Scientists have successfully implanted dopamine generators in brain cells, leading to improved symptoms in Parkinson's disease in non-human primates. The treatment involves injecting fragments of the carotid body into the striate area of the brain, which boosts the production of dopaminergic cells and increases dopamine release.
A new study from USC researchers found that treadmill exercise can improve balance and stability in patients with Parkinson's Disease. The study, published in the Journal of Neuroscience, suggests that exercise may help the brain work more efficiently by allowing remaining dopamine-producing neurons to function harder.
A randomized clinical trial found that a 300-milligram dose of CoQ10 did not improve Parkinson's disease symptoms in patients. However, the treatment was well-tolerated and increased blood levels of CoQ10, suggesting potential benefits at higher doses.
Parkinson's disease and narcolepsy share symptoms due to damage in the same small group of neurons. Researchers found that Parkinson's patients have severe loss of hypocretin cells, which may be reversible with treatments aimed at reversing this deficit.
Researchers found people taking antidepressant medications were nearly twice as likely to develop Parkinson's disease than those not taking the medication. Depression was identified as an early symptom of Parkinson's, appearing in the year before diagnosis.
Researchers found people taking levodopa were 95% more likely to choose symbols associated with higher monetary gains than those on haloperidol. Dopamine depletion may lead to lack of motivation in Parkinson's disease patients.
Researchers are developing nanotechnology to stimulate the body's healing abilities, enabling damaged organs to repair themselves. Early results show paralyzed lab mice regaining mobility after receiving a nanomaterial injection, offering hope for treating intractable diseases.
Research found that individuals with moderate to vigorous exercise levels were 40% less likely to develop Parkinson's disease than those with low activity levels. The study of over 143,000 people suggested a potential benefit of regular physical activity in reducing the risk of this debilitating condition.
A novel video-imaging system reveals that slow component-b proteins, involved in Parkinson's and Alzheimer's diseases, exhibit rapid bursts of movement followed by pauses. Multiple slow proteins are also transported together as 'packets,' piggy-backing on molecular motors, suggesting a potential carpooling mechanism.
Research reveals a strong link between stroke damage to brain region putamen and motor neglect, a condition causing slow movement on the left side. Treatment targeting dopamine-like compounds may ease this disability in patients with Parkinson's disease.
A study found that people who smoked and drank coffee were less likely to develop Parkinson's disease, which may be due to genetic or environmental factors. However, the risks of smoking and caffeine consumption should not be taken to avoid the disease.
Individuals with Parkinson's disease are less likely to smoke or consume high doses of caffeine than their family members. Smoking, caffeine consumption, and NSAID use were found to be inversely associated with Parkinson's disease, with no link between NSAID use observed.
Research highlights the role of pesticides, toxic agents, and inflammation in Parkinson's development, while also exploring potential neuroprotective agents like nicotine. The findings aim to better understand the disease process and develop preventive measures.
Researchers found that taking the prolonged release version of ropinirole with levodopa significantly reduced daily 'off' time by 2.1 hours compared to the placebo group. Additionally, those taking ropinirole showed improvements in troublesome Parkinson symptoms, quality of life, and motor function.
Researchers used massive computer-simulation power to model protein aggregation and its role in Parkinson's and Alzheimer's diseases. They found that beta-synuclein blocks harmful structures caused by alpha-synuclein, offering a potential treatment for debilitating diseases.
The NIH is launching a large-scale clinical trial to explore the potential of creatine as a treatment for Parkinson's disease. The study aims to slow the progression of the disease and improve quality of life for patients.
A two-year study found that the drug risedronate reduced hip fractures in people with Parkinson disease by three times compared to placebo. Risedronate also increased bone mineral density and decreased biomarkers for bone loss, effectively controlling osteoporosis progression.
A study by Max-Planck-Gesellschaft researchers found that disabling Ret-receptors in mice leads to earlier death of dopaminergic neurons, similar to Parkinson's disease. The loss of these neurons is a hallmark of the disease, and the study suggests that preserving this function may be crucial for preventing neurodegeneration.
Researchers at the University of Kentucky are exploring a novel gene therapy approach using DNA nanoparticles to deliver proteins beneficial to brain cells. This technology has shown potential in rescuing dormant brain cells, causing them to produce dopamine, and improving symptoms in animal models of Parkinson's disease.
Patients with Parkinson's disease who develop the condition at a younger age and have a history of alcohol abuse are more likely to experience pathological gambling as a side effect of dopamine agonist medications. Behavioral characteristics such as impulsivity and risk-taking behavior may also play a role in this increased risk.
A Stanford University study suggests that boosting endocannabinoid levels in the brain may be a new treatment approach for Parkinson's disease. Researchers combined a drug with an experimental compound to trigger improved movement in mice with a condition similar to Parkinson's, showing promising results.
GST pi is a critical enzyme that stands at the crossroads of several biochemical pathways leading to Parkinson's disease. It prevents both externally provoked cell death and internally initiated suicide by blocking the formation of free radicals, which cause cell damage.
Researchers have developed a new model of Parkinson's disease in fruit flies, confirming the link between dopamine and a mutant form of the parkin protein. The study found that a single copy of the mutation was toxic to dopaminergic neurons, leading to motor dysfunction.
The number of individuals with Parkinson's disease is projected to nearly double globally by 2030, with the majority of growth occurring in developing countries in Asia. This growth will be driven by increasing life expectancy and growing economies, which will lead to increased healthcare spending and a greater burden on societies.
A study published in Neurology found that zonisamide significantly improved tremors and dyskinesias in Parkinson disease patients. The medication was effective at 50mg/day, with a nearly 40% improvement in symptoms.
A study by Dr. Xuemei Huang found that participants with lower LDL cholesterol had a 3.5-fold higher occurrence of Parkinson's disease compared to those with higher LDL levels. The results suggest a link between low LDL cholesterol and an increased risk of developing the neurodegenerative disorder.
Researchers have discovered that transplanted neural stem cells can survive, differentiate into neurons, and form synapses with host tissue, potentially offering a new treatment for Parkinson's disease. The study shows promise in reducing the destruction of dopaminergic cells and replacing those lost to the disease.
A groundbreaking study by neurologist Steven Goldman and his team used stem cells to treat Parkinson's disease in rats, achieving a remarkable improvement in symptoms. However, brain tumors appeared due to the stem cells' uncontrolled growth, prompting an urgent need to find solutions.
A study published in Neurology found that people with Parkinson disease were more likely to make safety mistakes during a driving test than those without neurological disorders. The study involved an on-road driving test of participants with mild to moderate Parkinson disease and those of similar age without neurological disorders.
An alliance is being formed in India to conduct Parkinson's disease clinical trials, which will aid in the development of new treatments and slow down disease progression. The initiative aims to bring attention to the condition in India, where only a few neurologists specialize in movement disorders.
The Parkinson Study Group has received a $200,000 grant from the Parkinson's Disease Foundation to fund innovative programs supporting clinical research. The grant will support retrospective data-mining projects and mentorship for young researchers, aiming to accelerate treatment development.
Researchers found that dopamine deficiency in Parkinson's causes loss of muscle control and paralysis due to disruption of coordinated activity in a particular neural circuitry. A new treatment pathway aims to restore this dopamine-regulated circuitry coordination.
Neuroscientists at Duke University Medical Center discovered that critical nerve cells in mice fire all at the same time, overwhelming the brain's ability to control movement. This finding contradicts current theories behind Parkinson's disease and may help develop new therapeutics.
The Phase I trial demonstrated statistically significant clinical efficacy and neuro-imaging results, with patients showing a 25% improvement in Unified Parkinson's Disease Rating Scale scores. PET scan data revealed a significant improvement in brain metabolism on the treated side of the brain compared to the untreated side.
A Phase 1 study of CERE-120, a gene therapy product, demonstrated significant symptom reduction in patients with advanced Parkinson's disease, reducing UPDRS motor 'off' scores by approximately 40%. The treatment also showed promising results in improving 'on' time and reducing 'off' time.
Researchers found that dopamine plays a critical role in regulating sleep and brain activity associated with dreaming. Animal models of Parkinson's disease and schizophrenia exhibited sleep disturbances when dopamine levels were reduced or increased, suggesting a link between dopamine imbalances and sleep problems in these conditions.